Brown Advisory’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.3M Sell
110,470
-5,588
-5% -$240K 0.01% 540
2026
Q1
$4.27M Buy
116,058
+2,757
+2% +$131K 0.01% 557
2025
Q4
$5.76M Buy
113,301
+6,261
+6% +$320K 0.01% 520
2025
Q3
$5.94M Sell
107,040
-7,117
-6% -$417K 0.01% 505
2025
Q2
$7.88M Sell
114,157
-288
-0.3% -$19.6K 0.01% 445
2025
Q1
$7.95M Sell
114,445
-1,302
-1% -$108K 0.01% 435
2024
Q4
$9.96M Buy
115,747
+3,793
+3% +$410K 0.01% 430
2024
Q3
$13.3M Sell
111,954
-3,037
-3% -$405K 0.02% 377
2024
Q2
$16.4M Buy
114,991
+5,433
+5% +$720K 0.02% 344
2024
Q1
$14.1M Buy
109,558
+2,618
+2% +$312K 0.02% 368
2023
Q4
$11.1M Sell
106,940
-920
-0.9% -$91K 0.02% 393
2023
Q3
$9.81M Sell
107,860
-2,200
-2% -$194K 0.02% 388
2023
Q2
$8.91M Buy
110,060
+3,660
+3% +$299K 0.01% 409
2023
Q1
$8.47M Buy
106,400
+4,196
+4% +$298K 0.01% 412
2022
Q4
$6.92M Buy
102,204
+194
+0.2% +$11.4K 0.01% 426
2022
Q3
$5.08M Buy
102,010
+1,792
+2% +$96K 0.01% 449
2022
Q2
$5.58M Sell
100,218
-500
-0.5% -$27.7K 0.01% 445
2022
Q1
$5.59M Buy
100,718
+90,860
+922% +$4.66M 0.01% 460
2021
Q4
$552K Sell
9,858
-640
-6% -$34.7K ﹤0.01% 847
2021
Q3
$504K Sell
10,498
-1,828
-15% -$88.4K ﹤0.01% 825
2021
Q2
$515K Sell
12,326
-632
-5% -$24.5K ﹤0.01% 838
2021
Q1
$437K Buy
12,958
+1,452
+13% +$51.7K ﹤0.01% 869
2020
Q4
$401K Buy
11,506
+1,326
+13% +$45.8K ﹤0.01% 823
2020
Q3
$353K Sell
10,180
-874
-8% -$29.1K ﹤0.01% 796
2020
Q2
$362K Sell
11,054
-74
-0.7% -$2.36K ﹤0.01% 787
2020
Q1
$335K Sell
11,128
-80
-0.7% -$2.38K ﹤0.01% 764
2019
Q4
$324K Buy
+11,208
New +$310K ﹤0.01% 862
2019
Q3
Sell
-12,152
Closed -$310K 1027
2019
Q2
$310K Sell
12,152
-14,402
-54% -$356K ﹤0.01% 861
2019
Q1
$694K Sell
26,554
-1,456
-5% -$35.8K ﹤0.01% 899
2018
Q4
$645K Sell
28,010
-452
-2% -$10K ﹤0.01% 867
2018
Q3
$670K Sell
28,462
-1,182
-4% -$28.8K ﹤0.01% 919
2018
Q2
$684K Sell
29,644
-25,342
-46% -$602K ﹤0.01% 891
2018
Q1
$1.35M Buy
54,986
+40
+0.1% +$1.05K ﹤0.01% 591
2017
Q4
$1.48M Sell
54,946
-2,226
-4% -$56.6K ﹤0.01% 589
2017
Q3
$1.38M Sell
57,172
-5,126
-8% -$116K ﹤0.01% 592
2017
Q2
$1.34M Sell
62,298
-2,086
-3% -$42.1K ﹤0.01% 616
2017
Q1
$1.1M Buy
64,384
+10,778
+20% +$188K ﹤0.01% 620
2016
Q4
$962K Sell
53,606
-8,718
-14% -$158K ﹤0.01% 641
2016
Q3
$1.3M Sell
62,324
-5,098
-8% -$126K ﹤0.01% 567
2016
Q2
$1.81M Sell
67,422
-187,448
-74% -$5.14M 0.01% 513
2016
Q1
$6.91M Sell
254,870
-117,978
-32% -$3.16M 0.02% 321
2015
Q4
$10.8M Buy
372,848
+37,410
+11% +$1.04M 0.04% 271
2015
Q3
$9.1M Buy
335,438
+44,162
+15% +$1.25M 0.03% 284
2015
Q2
$7.98M Sell
291,276
-4,514
-2% -$127K 0.03% 295
2015
Q1
$7.9M Sell
295,790
-74,064
-20% -$1.71M 0.03% 300
2014
Q4
$7.83M Buy
369,854
+36,578
+11% +$817K 0.02% 299
2014
Q3
$7.93M Buy
333,276
+302,978
+1,000% +$6.97M 0.03% 299
2014
Q2
$699K Buy
30,298
+188
+0.6% +$4.15K ﹤0.01% 615
2014
Q1
$687K Sell
30,110
-1,990
-6% -$42.4K ﹤0.01% 605
2013
Q4
$593K Buy
+32,100
New +$559K ﹤0.01% 612

Other funds holding NVO

Brown Advisory's NVO Position: Q2 2026 in Review

Brown Advisory reduced its Novo Nordisk (NVO) stake by 4.8% in Q2 2026, selling an estimated $240K and leaving 110,470 shares worth $5.3M. The position accounts for 0.01% of the portfolio, ranked #540.

Brown Advisory first reported a position in NVO in Q4 2013 and has held it in 50 quarters since. The position peaked at $16.4M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Brown Advisory held 110,470 shares of Novo Nordisk worth $5.3M as of Q2 2026.
  • Brown Advisory sold 5,588 Novo Nordisk shares in Q2 2026, an estimated $240K.
  • Novo Nordisk made up 0.01% of Brown Advisory's portfolio in Q2 2026, its #540 holding.
  • Brown Advisory first reported a position in Novo Nordisk in Q4 2013 and has held it in 50 quarters since.
  • Brown Advisory's Novo Nordisk position peaked at $16.4M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.